If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMicrosaic Regulatory News (MSYS)

  • There is currently no data for MSYS

Directorate Change

19 Dec 2017 07:00

RNS Number : 7196Z
Microsaic Systems plc
19 December 2017
 

19th December 2017

Microsaic Systems plc

("Microsaic" or the "Company")

Directorate Change

Microsaic Systems plc (AIM: MSYS), the developer of chip-based mass spectrometry ("MS") instruments designed to improve the efficiency of pharmaceutical R&D, is pleased to announce the appointment of Peter Grant MA (Oxon.), FCA to the position of Non-Executive Chairman, with effect from January 1, 2018.

 

Peter comes from a background in pharmaceuticals, electronics, engineering and financial services, where he has a successful track record of commercialising technology, high growth, turnarounds, working capital reductions and mergers and acquisitions. His skills and experience are expected to be particularly relevant to Microsaic as it progresses into the next stages of development.

Mr Grant has had an executive career spanning 40 years, nearly half at listed company board level, as CEO/CFO, including both London main market (up to FTSE 250) and AIM. His executive career included CEO of Skyepharma PLC, which, during his tenure, was transformed onto a strong growth path, CFO of Skyepharma PLC, Group Finance Director at Eurodis Electron PLC, Chief Financial Officer at WorldPay Group plc, Group Chief Executive at Molins PLC and Finance Director at Molins PLC. Prior to this he held a variety of senior commercial, financial and general management roles in the General Electric Company PLC group of companies.

Peter will chair the Finance and Audit Committee, and be a member of the Remuneration Committee of the Company.

Peter is Chairman of LiDCO Group Plc, Non-Executive Director and Chair of the Audit and Risk Committee of Abzena plc, and a Non-Executive Director of Labatec Pharma SA.

Eric Yeatman will step down as Interim Chairman of the Board with effect from 1 January 2018, and will remain a Non-Executive Director, Chairman of the Remuneration Committee, and member of the Finance and Audit Committee.

Glenn Tracey, CEO of Microsaic Systems plc, commented:

"We are delighted to welcome someone of Peter's calibre to the board as Chairman. We look forward to benefitting from the breadth of Peter's business experience and industry knowledge. I would like to take this opportunity to thank Eric Yeatman for acting as Interim Chairman since 31 January 2017."

Peter Grant commented:

"I am looking forward to joining such an innovative company and working with Glenn and the rest of the team to achieve Microsaic's potential. We will ensure that we have the right mix of skills and experience needed, have simple and transparent structures and importantly that we put our innovation and clients first."

Additional information on Mr Peter Grant

The following additional information is provided in accordance with paragraph (g) of Schedule Two to the AIM Rules for Companies:

Peter William Grant (aged 62), holds or held the following Directorships or Partnerships in the past 5 years:

Current Directorships/Partnerships

Past Directorships/Partnerships

 

Abzena PLC

LiDCO Group PLC

Labatec Pharma SA

 

Searching Solutions Ltd1

Skyepharma PLC

SkyePharma Holding AG

SkyePharma AG

Skyepharma Management AG

Jagotec AG

Jago Holding AG

Skyepharma Holding Inc

Skyepharma US Inc

Skyepharma (Jersey) Limited

Bolag nr 16 i Malmö AB

Krypton Limited

Vine Northern Limited

Vine Industries Limited

Vinestand Limited

Playscheme Limited

Sun Wharf (Stratford) Limited

Vine Exhibition Limited

Vine (Building Maintenance) Limited

Big Ben Scaffolding Limited

 

 

1 Currently in solvent voluntary strike off

 

 

Mr Grant resigned from the board of Eurodis Electron PLC in January 2005 for family health reasons. In March 2005, a major franchiser gave notice of termination of its relationship with Eurodis Electron PLC, and in July 2005 the lead finance provider to Eurodis Electron PLC reduced the facilities and the company (and a number of its subsidiaries) went into administration.

 

Peter currently holds no interest in the ordinary share capital, or other securities, of Microsaic Systems plc.

There is no other information that is required to be disclosed pursuant to paragraph (g) of Schedule Two to the AIM Rules for Companies.

This announcement is released by Microsaic Systems plc and contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 ("MAR"), encompassing information relating to the board change described herein, and is disclosed in accordance with the Company's obligations under Article 17 of MAR.

For the purposes of MAR and Article 2 of Commission Implementing Regulation (EU) 2016/1055, this announcement is being made on behalf of the Company by Glenn Tracey, CEO.

Enquiries:

Microsaic Systems plc

Glenn Tracey, CEO

Bevan Metcalf, FD

 

+44 (0) 1483 751577

N+1 Singer (Nominated Adviser & Broker)

Shaun Dobson

Liz Yong

 

 +44 (0)20 7496 3000

IFC Advisory (Financial PR)

Graham Herring

Heather Armstrong

Florence Chandler

+44 (0)20 7638 9571

 

 

About Microsaic Systems

Microsaic Systems plc (AIM: MSYS) is a high technology company developing chip-based, bench-top and point-of-analysis mass spectrometry ("MS") instruments that are designed to improve the efficiency of pharmaceutical R&D. The Company is working with established global life science companies to co-develop new solutions to improve productivity in the development of small molecule and novel biologic (peptides, antibodies) medicines. MS is a powerful method of analysis to enable earlier decision making relating to product identification, purity and bioactivity, and is the analytical technique of choice for biochemists across many industry sectors.

 

Microsaic's core product, the 4000 MiD(R), is one of the smallest MS systems in the world, retaining the functionality of larger conventional MS systems, is easier to use by non-specialists, consumes less energy and has lower running costs. For more information, please go to www.microsaic.com.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOALVLLFDLFLFBQ
Date   Source Headline
28th Oct 20149:16 amRNSHolding(s) in Company
14th Oct 20142:10 pmRNSHolding(s) in Company
10th Oct 20144:19 pmRNSHolding(s) in Company
10th Oct 20141:15 pmRNSExercise of Share Options
8th Oct 20147:00 amRNSDirectors' Dealings
7th Oct 20147:00 amRNSConditional Placing to Raise £4.4 million
30th Sep 20147:00 amRNSInterim Results
29th Sep 201412:23 pmRNSCommercial Agreement with Gilson Inc.
25th Sep 20147:00 amRNSMicrosaic Systems Signs Commercial Agreement
9th Sep 20147:00 amRNSPlexus chosen as commercial manufacturing partner
15th Jul 201410:06 amRNSDirectorate Change
23rd Jun 20143:08 pmRNSHolding(s) in Company
19th Jun 201412:02 pmRNSHolding(s) in Company
13th Jun 20149:00 amRNSDISTRIBUTION OF ANNUAL REPORT & ACCOUNTS
10th Jun 20149:10 amRNSExercise of share options
3rd Jun 20147:00 amRNSResult of AGM
30th May 20141:09 pmRNSNotification of Major Interest in Shares
6th May 201411:58 amRNSGRANT OF SHARE OPTIONS
30th Apr 20147:00 amRNSPreliminary Results
28th Apr 201412:33 pmRNSNotification of Major Interest in Shares
23rd Apr 20148:18 amRNSNotification of Major Interest in Shares
17th Apr 20149:19 amRNSHolding(s) in Company
15th Apr 20149:17 amRNSAppointment of Finance Director
14th Apr 20149:42 amRNSRe Agreement
11th Dec 20133:56 pmRNSHolding(s) in Company
21st Oct 20137:00 amRNSFormation of new Scientific Advisory Group
27th Sep 20137:00 amRNSInterim Results
1st Jul 20137:00 amRNSAppointment of Chairman
24th Jun 20137:00 amRNSIssue of Equity
4th Jun 20135:08 pmRNSHolding(s) in Company
4th Jun 20137:00 amRNSMicrosaic welcomes launch of the IsoleraT Dalton
31st May 201310:28 amRNSHolding(s) in Company
28th May 20132:44 pmRNSHolding(s) in Company
24th May 201311:23 amRNSResults of General Meeting
15th May 201311:23 amRNSResults of Annual General Meeting
7th May 20134:35 pmRNSDistribution of Circular of General Meeting
3rd May 20136:25 pmRNSConditional Placing to Raise up to £4.28 million
22nd Apr 20137:00 amRNSDistribution of Annual Report and Accounts
15th Apr 20137:00 amRNSPreliminary Results
10th Apr 20137:00 amRNSSigning of commercial agreement
15th Mar 20131:05 pmRNSHolding(s) in Company
14th Mar 20139:00 amRNSLaunch New Chip-based Mass Spectrometry Instrument
12th Dec 20129:36 amRNSGrant of Share Options
19th Oct 20124:45 pmRNSDirector/PDMR Shareholding
15th Oct 20122:26 pmRNSDirector/PDMR Shareholding
24th Sep 20127:00 amRNSAppointment of new CEO
24th Sep 20127:00 amRNSInterim Results
4th Sep 201210:00 amRNSAgreement
4th Jul 20129:46 amRNSGrant of Share Options
25th Jun 201210:29 amRNSMicrosaic Wins R&D100 Award

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.